SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Corona Remedies informs about investor meetings

03 Jun 2026 Evaluate

Pursuant to Regulation 30 read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended from time to time, Corona Remedies has informed that the Officials of the Company will be participating in a Non-Deal Roadshow (NDR) to meet Investors on June 08, 2026 and June 09, 2026 at 09:00 am (SST) onwards organized by IIFL Capital in Singapore (1x1). Discussions will be based on publicly available information. No unpublished price sensitive information (UPSI) will be discussed during the said Meetings. This intimation is also being made available on the website of the Company at www.coronaremedies.com.

The above information is a part of company’s filings submitted to BSE. 

CORONA Remedies Share Price

1832.65 40.30 (2.25%)
18-Jun-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1824.00
Dr. Reddys Lab 1267.80
Cipla 1355.80
Zydus Lifesciences 1074.30
Lupin 2327.50
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: